Plain-English translation of NCT06315491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called CBX 12 to see if it can help women whose ovarian cancer has become resistant to standard platinum-based chemotherapy treatments. Researchers will give participants one of two doses of the medication every 3 weeks and carefully monitor how well it works and how safe it is. This is an early-stage trial designed to understand whether this treatment is a promising option for people in this difficult situation.
Ovarian cancer that stops responding to platinum chemotherapy is very difficult to treat, and patients need new options. This medication is being tested to see if it can help people whose cancer has become resistant to standard therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through an IV) every 3 weeks. The study will assign you randomly to receive one of two dose levels. You will continue treatment as long as the medication is helping and side effects remain manageable, with regular clinic visits to check your health, blood work, and how your cancer is responding to the treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States